Genetic mutations in the treatment of anaplastic thyroid cancer: A systematic review

BMC Surgery

Volumn 13, Issue SUPPL.2, 2013, Pages

  Guerra, Anna ^a   Di Crescenzo, Vincenzo ^a   Garzi, Alfredo ^a   Cinelli, Mariapia ^b   Carlomagno, Chiara ^b   Tonacchera, Massimo ^c   Zeppa, Pio ^a   Vitale, Mario ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GENETICS; HUMAN; MUTATION; REVIEW; THYROID TUMOR;

HUMANS; MUTATION; THYROID NEOPLASMS;

EID: 84885348643     PISSN: None     EISSN: 14712482     Source Type: Journal    
DOI: 10.1186/1471-2482-13-S2-S44     Document Type: Article

References (68)

1. Parapharyngeal ectopic thyroid: the possible persistence of the lateral thyroid anlage. Clinical case report. Soscia A, Guerra G, Cinelli MP, Testa D, Galli V, Macchi V, De Caro R, Surg Radiol Anat 2004 26 4 338 343 15138715 (Pubitemid 39193890)
2. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, et al. Thyroid 2009 19 11 1167 1214 19860577
3. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, et al. N Engl J Med 2012 367 8 705 715 22731672
4. Lymph nodes fine needle cytology in the diagnosis of infectious diseases: cytological and histological correlations. Cozzolino I, Scognamiglio G, Sosa Fernandez LV, Zeppa P, Infez Med 2012 20 Suppl 3 16 20 23069688
5. Thyroid Cytopathology: A Text and Atlas. Kini SR, Lippincott Williams & Wilkins 2008 24047372
6. Diagnostic use of molecular markers in the evaluation of thyroid nodules. Kim MI, Alexander EK, Endocr Pract 2012 18 5 796 802 22982803
7. Lymph node fine needle cytology in the diagnosis of infectious diseases and reactive unspecific processes. Cipullo C, Amato B, Vigliar E, Di Crescenzo V, Zeppa P, Infez Med 2012 20 Suppl 3 30 33 23069691
8. BRAFV600E assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay. Guerra A, Di Stasi V, Zeppa P, Faggiano A, Marotta V, Vitale M, Endocrine 2013
9. Calcium-calmodulin-dependent kinase II (CaMKII) mediates insulin-stimulated proliferation and glucose uptake. Illario M, Monaco S, Cavallo AL, Esposito I, Formisano P, D'Andrea L, Cipolletta E, Trimarco B, Fenzi G, Rossi G, et al. Cell Signal 2009 21 5 786 792 19171190
10. Thyroid surgery in geriatric patients: a literature review. Gervasi R, Orlando G, Lerose MA, Amato B, Docimo G, Zeppa P, Puzziello A, BMC Surg 2012 12 Suppl 1 16 23173919
11. Thyroid surgery in the geriatric patient. Passler C, Avanessian R, Kaczirek K, Prager G, Scheuba C, Niederle B, Arch Surg 2002 137 11 1243 1248 12413310 (Pubitemid 35345895)
12. Hematopoietic progenitor and stem cells circulate by surfing on intracellular Ca2+ waves: A novel target for cell-based therapy and anti-cancer treatment? Moccia F, Bonetti E, Dragoni S, Fontana J, Lodola F, Berra Romani R, Laforenza U, Rosti V, Tanzi F, Curr Signal Transd T 2012 7 7 161 176
13. Store-dependent Ca(2+) entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization. Moccia F, Dragoni S, Lodola F, Bonetti E, Bottino C, Guerra G, Laforenza U, Rosti V, Tanzi F, Curr Med Chem 2012 19 34 5802 5818 22963562
14. Canonical Transient Receptor Potential 3 channel triggers VEGF-induced intracellular ca2+ oscillations in endothelial progenitor cells isolated from umbilical cord blood. Dragoni S, Laforenza U, Bonetti E, Lodola F, Bottino C, Guerra G, Borghesi A, Stronati M, Rosti V, Tanzi F, Moccia F, Stem Cells and Development 2013 22 19 2561 2580 23682725
15. SEREX: a promising approach for identification of thyroid cancer serological biomarkers. Vitale M, Clin Endocrinol (Oxf) 2013
16. Oxidative stress in chronic otitis media with effusion. Testa D, Guerra G, Marcuccio G, Landolfo PG, Motta G, Acta oto-laryngologica 2012 132 8 834 837 22497729
17. NADPH-oxidase-dependent reactive oxygen species mediate EGFR transactivation by FPRL1 in WKYMVm-stimulated human lung cancer cells. Cattaneo F, Iaccio A, Guerra G, Montagnani S, Ammendola R, Free radical biology and medicine 2011 51 6 1126 1136 21708247
18. Aerobic training workload affects human endothelial cells redox homeostasis. Conti V, Russomanno G, Corbi G, Guerra G, Grasso C, Filippelli W, Paribello V, Ferrara N, Filippelli A, Medicine and science in sports and exercise 2013 45 4 644 653 23135374
19. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA, J Clin Invest 1993 91 4 1753 1760 8473515 (Pubitemid 23127381)
20. Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients. Lodola F, Laforenza U, Bonetti E, Lim D, Dragoni S, Bottino C, Ong HL, Guerra G, Ganini C, Massa M, et al. PLoS One 2012 7 9 42541 23049731
21. Store-operated Ca(2+) entry is expressed in human endothelial progenitor cells. Sanchez-Hernandez Y, Laforenza U, Bonetti E, Fontana J, Dragoni S, Russo M, Avelino-Cruz JE, Schinelli S, Testa D, Guerra G, et al. Stem Cells Dev 2010 19 12 1967 1981 20677912
22. Calcium channels and prostate cancer. Shapovalov G, Skryma R, Prevarskaya N, Recent Pat Anticancer Drug Discov 2013 8 1 18 26 22694290
23. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present. Marotta V, Guerra A, Zatelli MC, Uberti ED, Stasi VD, Faggiano A, Colao A, Vitale M, Clin Endocrinol (Oxf) 2013
24. Rethinking the role of oncogenes in papillary thyroid cancer initiation. Vitale M, Front Endocrinol (Lausanne) 2012 3 83
25. RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Marotta V, Guerra A, Sapio MR, Vitale M, Eur J Endocrinol 2011 165 4 499 507 21750045
26. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, Parangi S, Endocrinology 2012 153 2 985 994 22202162
27. BRAF V600E inhibition in anaplastic thyroid cancer. Rosove MH, Peddi PF, Glaspy JA, N Engl J Med 2013 368 7 684 685 23406047
28. Cytologic, flow cytometry, and molecular assessment of lymphoid infiltrate in fine-needle cytology samples of Hashimoto thyroiditis. Zeppa P, Cozzolino I, Peluso AL, Troncone G, Lucariello A, Picardi M, Carella C, Pane F, Vetrani A, Palombini L, Cancer 2009 117 3 174 184 19382168
29. Non lymphomatous clonal B-Cell populations in enlarged lymph nodes in acquired immunodeficiency syndrome. Cozzolino I, Vigliar E, Sosa Fernandez LV, Selleri C, Pepe S, Vitale M, Triggiani M, Zeppa P, Infez Med 2012 20 Suppl 2 35 42 22982696
30. Cytological and histological detection of amyloid deposits in bone marrow of patients affected by multiple myeloma. Petruzziello F, Zeppa P, Ciancia G, Cozzolino I, Fernandez LS, Cervasio M, Musto P, D'Auria F, Vita G, Morabito F, et al. Leuk Lymphoma 2011 52 12 2304 2307 21718137
31. Clonal B-cell population in a reactive lymph node in acquired immunodeficiency syndrome. Cozzolino I, Nappa S, Picardi M, De Renzo A, Troncone G, Palombini L, Zeppa P, Diagn Cytopathol 2009 37 12 910 914 19582804
32. Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Guerra A, Sapio MR, Marotta V, Campanile E, Moretti MI, Deandrea M, Motta M, Limone PP, Fenzi G, Rossi G, et al. Endocr J 2011 58 1 31 38 21173509
33. High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. Sapio MR, Guerra A, Marotta V, Campanile E, Formisano R, Deandrea M, Motta M, Limone PP, Fenzi G, Rossi G, et al. J Clin Endocrinol Metab 2011 96 6 916 919 21411555
34. Growing thyroid nodules with benign histology and RET rearrangement. Marotta V, Guerra A, Sapio MR, Campanile E, Motta M, Fenzi G, Rossi G, Vitale M, Endocr J 2010 57 12 1081 1087 21048359
35. Phase II trial of sorafenib in advanced thyroid cancer. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, et al. J Clin Oncol 2008 26 29 4714 4719 18541894
36. Molecular pathogenesis and mechanisms of thyroid cancer. Xing M, Nat Rev Cancer 2013 13 3 184 199 23429735
37. BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma. Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Caleo A, Zeppa P, Esposito S, Fulciniti F, Vitale M, Endocrine 2013
38. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. N Engl J Med 2011 364 26 2507 2516 21639808
39. Intratumor BRAFV600E heterogeneity and kinase inhibitors in the treatment of thyroid cancer: a call for participation. Vitale M, Thyroid 2013
40. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A, Vitale M, J Clin Endocrinol Metab 2012 97 7 2333 2340 22508706
41. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al. Nature 2010 468 7326 973 977 21107323
42. The Primary Occurrence of BRAFV600E Is a Rare Clonal Event in Papillary Thyroid Carcinoma. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G, et al. J Clin Endocrinol Metab 2012 97 2 517 524 22170714
43. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, et al. Cancer Res 2009 69 11 4885 4893 19487299
44. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M, J Clin Endocrinol Metab 2008 93 8 3106 3116 18492751
45. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, et al. Mol Cancer Ther 2010 9 7 1956 1967 20571069
46. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M, J Clin Endocrinol Metab 2011 96 4 577 585 21289267
47. Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. Papewalis C, Wuttke M, Schinner S, Willenberg HS, Baran AM, Scherbaum WA, Schott M, Horm Metab Res 2009 41 10 752 756 19513966
48. Targeted therapy with kinase inhibitors in aggressive endocrine tumors. Marotta V, Franzese MD, Del Prete M, Chiofalo MG, Ramundo V, Esposito R, Marciello F, Pezzullo L, Carratu A, Vitale M, et al. Expert Opin Pharmacother 2013 14 9 1187 1203 23675883
49. Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP system. Nagayama Y, Nishihara E, Namba H, Yokoi H, Hasegawa M, Mizuguchi H, Hayakawa T, Hamada H, Yamashita S, Niwa M, Cancer Gene Ther 2001 8 1 36 44 11219492 (Pubitemid 32151895)
50. ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. Portella G, Scala S, Vitagliano D, Vecchio G, Fusco A, J Clin Endocrinol Metab 2002 87 6 2525 2531 12050209 (Pubitemid 34655309)
51. BRAF mutations in papillary carcinomas of the thyroid. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S, Oncogene 2003 22 41 6455 6457 14508525 (Pubitemid 37281692)
52. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S, J Clin Endocrinol Metab 2003 88 9 4393 4397 12970315 (Pubitemid 37153748)
53. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, et al. J Clin Endocrinol Metab 2003 88 11 5399 5404 14602780 (Pubitemid 37452745)
54. BRAF T1796A transversion mutation in various thyroid neoplasms. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D, J Clin Endocrinol Metab 2004 89 3 1365 1368 15001635 (Pubitemid 38368438)
55. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH, Mod Pathol 2004 17 11 1359 1363 15195111 (Pubitemid 39472990)
56. BRAF mutations in an Italian cohort of thyroid cancers. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P, Clin Endocrinol (Oxf) 2004 61 2 239 243 (Pubitemid 39093120)
57. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Soares P, Trovisco V, Rocha AS, Feijao T, Rebocho AP, Fonseca E, Vieira de Castro I, Cameselle-Teijeiro J, Cardoso-Oliveira M, Sobrinho-Simoes M, Virchows Arch 2004 444 6 572 576 15095090 (Pubitemid 38858382)
58. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI, J Clin Endocrinol Metab 2008 93 1 278 284 17989125
59. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Manenti G, Pilotti S, Re FC, Della Porta G, Pierotti MA, Eur J Cancer 1994 30A 7 987 993 7946598 (Pubitemid 24256250)
60. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G, J Clin Oncol 2003 21 17 3226 3235 12947056 (Pubitemid 46606254)
61. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, et al. Clin Cancer Res 2007 13 4 1161 1170 17317825 (Pubitemid 46424056)
62. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E, Iacconi P, Miccoli P, Pacini F, Thyroid 2000 10 1 19 23 10691309 (Pubitemid 30090361)
63. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components. Mochizuki K, Kondo T, Nakazawa T, Iwashina M, Kawasaki T, Nakamura N, Yamane T, Murata S, Ito K, Kameyama K, et al. Histopathology 2010 57 3 444 450 20840674
64. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A, Clin Cancer Res 1998 4 2 287 294 9516913 (Pubitemid 28122740)
65. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, et al. Cancer Res 1997 57 21 4710 4713 9354427 (Pubitemid 27468972)
66. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M, Cancer Res 2005 65 22 10199 10207 16288007 (Pubitemid 41743711)
67. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP, J Clin Invest 1993 91 1 179 184 8423216 (Pubitemid 23037270)
68. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N, Akiyama M, Cancer Res 1992 52 5 1369 1371 1737400